Baxter International (NYSE: BAX) announced that they have been approval by a European repeat mutual recognition procedure (rMRP), at the Austrian Agency for Health and Food Safety to begin providing it’s PREFLUCEL seasonal influenza vaccine for the 2011-12 flu season.
PREFLUCEL is manufactured via a patented cellular process (“Vero”), rather than the traditional embryonated chicken egg production process.
A study recently published in The Lancet showed a 78.5 percent protective efficacy.
The Baxter International release is here
http://www.baxter.com/press_room/press_releases/2011/03_02_11_preflucel_europe.html
No comments:
Post a Comment